Adimmune Corporation (TPE:4142)
Taiwan · Delayed Price · Currency is TWD 17.15
+0.20 (1.18%)
May 29, 2026, 1:30 PM CST
Adimmune Revenue
Adimmune had revenue of 82.32M TWD in the quarter ending March 31, 2026, with 14.16% growth. This brings the company's revenue in the last twelve months to 1.41B, down -10.95% year-over-year. In the year 2025, Adimmune had annual revenue of 1.40B, down -9.99%.
Revenue (ttm)
1.41B
Revenue Growth
-10.95%
P/S Ratio
5.12
Revenue / Employee
2.50M
Employees
564
Market Cap
7.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.40B | -155.49M | -9.99% |
| Dec 31, 2024 | 1.56B | -228.11M | -12.78% |
| Dec 31, 2023 | 1.79B | -466.53M | -20.72% |
| Dec 31, 2022 | 2.25B | 457.85M | 25.52% |
| Dec 31, 2021 | 1.79B | -75.37M | -4.03% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sinphar Pharmaceutical | 3.39B |
| Panion & Bf Biotech | 2.10B |
| Savior Lifetec | 1.17B |
| PharmaEngine | 963.83M |
| Mycenax Biotech | 815.34M |
| Tanvex BioPharma | 483.94M |
| TaiGen Biopharmaceuticals Holdings | 258.93M |
| Gongwin Biopharm Holdings | 38.28M |